These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [When lipids increase in dialysis: the role of heparin! Standard heparin increases, low-molecular-weight heparin lowers triglycerides]. Wiemer J; Scherberich JE MMW Fortschr Med; 1999 Oct; 141(43):29-32. PubMed ID: 10912118 [TBL] [Abstract][Full Text] [Related]
3. [Lipaemic profile of patients subjected to long-term haemodialysis and acute changes associated with haemodialysis and the use of heparin (author's transl)]. Koslík S; Takác M Sb Lek; 1981 Jul; 83(6-7):162-8. PubMed ID: 7268304 [No Abstract] [Full Text] [Related]
4. [Levels of serum lipids and lipoproteins in renal disease]. Synková J; Groh J; Sedová J; Mejtská M Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1981; 24(3):373-84. PubMed ID: 6977835 [No Abstract] [Full Text] [Related]
5. [Effects of low molecular weight heparin as an anti-coagulant for hemodialysis]. Akizawa T; Kanamori N; Koshikawa S Rinsho Byori; 1990 Jul; Suppl 86():171-6. PubMed ID: 2172593 [No Abstract] [Full Text] [Related]
6. Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure. Lane DA; Ireland H; Tew CJ; Flynn A; Curtis JR Acta Chir Scand Suppl; 1988; 543():101-4. PubMed ID: 2847457 [TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Schmitt Y; Schneider H Nephrol Dial Transplant; 1993; 8(5):438-42. PubMed ID: 8393549 [TBL] [Abstract][Full Text] [Related]
10. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait. Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883 [TBL] [Abstract][Full Text] [Related]
11. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis. Liu ZQ; Wang L Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628 [TBL] [Abstract][Full Text] [Related]
12. [Lipid content of plasma in patients with chronic renal failure during hemodialysis treatment]. Dembitskiĭ VM; Malyĭ VN Urol Nefrol (Mosk); 1984; (3):57-9. PubMed ID: 6740820 [No Abstract] [Full Text] [Related]
13. [Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients]. Drozdz M; Kowalczyk-Michałek M; Kraśniak A; Sułowicz W Przegl Lek; 2005; 62(4):257-9. PubMed ID: 16229247 [TBL] [Abstract][Full Text] [Related]
14. Anti-factor Xa determination in blood: a new method for controlling heparin therapy. Harenberg J; Haaf B; Schäfer M; Dempfle CE; Stehle G; Heene DL Semin Thromb Hemost; 1993; 19 Suppl 1():79-85. PubMed ID: 8395736 [No Abstract] [Full Text] [Related]
19. [Use of low-molecular weight heparin during hemodialysis]. Kalinowski M; Pawlak K; Myśliwiec M; Popławski A Pol Merkur Lekarski; 1997 Jan; 2(9):208-10. PubMed ID: 10907031 [TBL] [Abstract][Full Text] [Related]